AstraZeneca gets an additional FDA approval for its diabetes drug

The Food and Drug Administration approved AstraZeneca's drug Farxiga as a treatment for reducing the risk of hospitalizations for heart failure in adults with type-2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Farxiga, developed by AstraZeneca (NYSE: AZN) in a partnership with Bristol-Myers Squibb, already had FDA approval as a therapy along with diet and exercise to lower blood sugar in adults with type 2 diabetes. The drug generated sales of more than…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

ConclusionsIn this observational analysis of T2D and ASCVD, baseline β-blocker use was not associated with risks for severe hypoglycemia yet also was not associated with CV risk reduction over 3 years of follow-up, supporting a randomized examination of chronic β-blocker therapy in this patient population. (TECOS ClinicalTrials.gov number, NCT00790205).
Source: American Heart Journal - Category: Cardiology Source Type: research
Publication date: Available online 6 November 2019Source: JACC: Heart FailureAuthor(s): Milton PackerAbstractBoth obesity and type 2 diabetes are important risk factors for the development of heart failure with a preserved ejection fraction (HFpEF), and both disorders increase the risk of systemic thromboembolic events. Traditionally, the risk of stroke has been explained by the strong association of these disorders with atrial fibrillation (AF). However, adiposity and diabetes are risk factors for systemic thromboembolism, even in the absence of AF, because both can lead to the development of an inflammatory and fibrotic ...
Source: JACC: Heart Failure - Category: Cardiology Source Type: research
This study was designed to evaluate the influences of long-term metformin prescription in these patients.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Menarche is an important event in a woman's life and is defined as the first menstrual cycle. The age at menarche (AAM) is often seen as a marker for the start of puberty in women. In previous research early menarche has shown to increase the risk of developing overweight [1] and type 2 diabetes (T2D) in adulthood [2]. In addition, both early- and late menarche has been associated with an increased risk of developing hypertension and coronary heart disease (CHD) in large UK studies [3,4].
Source: Maturitas - Category: Primary Care Authors: Source Type: research
Patients with type 2 diabetes (T2D) have approximately twice the risk of developing cardiovascular (CV) disease (CVD) [1] and a 2.5-fold increased risk of heart failure (HF) [2] compared with individuals without diabetes. Every 1-mmol/L (18-mg/dL) increase in fasting glucose levels increases the risk of CV events or death by 17% [3]. Results from studies investigating the impact of intensive glucose lowering are contradictory. Early trials comparing intensive glucose control versus standard therapy failed to demonstrate reduced CV mortality [4 –7], and benefits for CV risk reduction have only emerged after long-term ...
Source: Primary Care Diabetes - Category: Primary Care Authors: Tags: Review Source Type: research
In 2008, the European Medicines Agency and US Food and Drug Administration (FDA) issued industry guidance stating that all future novel glucose-lowering agent trials must undergo routine cardiovascular risk evaluation either before approval or as a post-marketing commitment.1 This mandated that all cardiovascular endpoint committees prospectively adjudicate all major adverse cardiovascular events, including cardiovascular death, non-fatal MI and stroke, occurring across Phase II and III diabetes trials.
Source: Radcliffe Cardiology - Category: Cardiology Authors: Source Type: research
In this study, we hypothesized that moderately and chronically reducing ACh could attenuate the deleterious effects of aging on NMJs and skeletal muscles. To test this hypothesis, we analyzed NMJs and muscle fibers from heterozygous transgenic mice with reduced expression of the vesicular ACh transporter (VAChT), VKDHet mice, which present with approximately 30% less synaptic ACh compared to control mice. Because ACh is constitutively decreased in VKDHet, we first analyzed developing NMJs and muscle fibers. We found no obvious morphological or molecular differences between NMJs and muscle fibers of VKDHet and contro...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
CONCLUSION: Even if many new effective hypoglycemic agents have been launched in the market in the last few years, Metformin would always keep a place in the treatment of type 2 diabetes and its comorbidities because of its multiple positive effects and low cost. PMID: 31670618 [PubMed - as supplied by publisher]
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
A rapidly aging U.S. population, as well as high rates of obesity and diabetes, are causing more people to die from heart failure and other heart problems, according to a new report published in JAMA Cardiology. That’s bad news not only for patients, but also for the U.S. health care system. Heart disease remains the leading killer of Americans, but improvements in public health and medicine over the last few decades have driven cardiovascular mortality rates way down. In recent years, however, that progress has slowed, and declines in heart disease mortality have been more modest. Some studies even suggest cardiovas...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized medicine onetime Source Type: news
ConclusionsA diverse set of potential mediators of the effect of canagliflozin on heart failure were identified. Some mediating effects were anticipated, whereas others were not. The mediators that were identified support existing and novel hypothesized mechanisms for the prevention of heart failure with sodium glucose cotransporter 2 inhibitors.Central Illustration
Source: JACC: Heart Failure - Category: Cardiology Source Type: research
More News: AstraZeneca | Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Diets | Endocrinology | Food and Drug Administration (FDA) | Health Management | Heart | Heart Failure | Nutrition | Partnerships | Pharmaceuticals | Sports Medicine | Sugar